Mr. Ghulam Muhayyudin Chattha, at Federal University of Rio Grande do Sul (UFRGS), Brazil.
Ghulam Muhayyudin Chattha is a Pakistani pharmaceutical scientist born on December 9, 1998, in Porto Alegre, Brazil. Currently pursuing a Master’s in Pharmaceutical Sciences at Universidade Federal do Rio Grande do Sul (UFRGS), Brazil, he holds a Pharm-D degree from the University of Sargodha, Pakistan. His academic journey reflects a commitment to advancing pharmaceutical sciences through rigorous education and research. Chattha’s work bridges international perspectives, contributing to the global discourse on pharmaceutical innovations.
Professional Profile
ORCID
Education
Chattha’s educational foundation in pharmaceutical sciences began with his secondary education in Gujranwala, Pakistan, followed by pre-medical studies at Punjab College of Commerce. He earned his Pharm-D degree from the University of Sargodha, achieving a CGPA of 3.55/4. Currently, he is pursuing a Master’s in Pharmaceutical Sciences at UFRGS, Brazil, focusing on advanced drug delivery systems and nanotechnology. His academic path showcases a dedication to acquiring comprehensive knowledge in pharmaceutical sciences.
Experience
Chattha’s professional experience encompasses roles in academia and clinical pharmacy. As a lecturer at Ahmad College of Pharmacy, he delivered lectures and assisted students during laboratory sessions, fostering a scientific approach to learning. His internships at Dispensary Pharmacy and DHQ Teaching Hospital involved advising patients on medication use and maintaining pharmacy operations. These experiences have honed his practical skills in patient care and pharmaceutical education.
Research Interests
Chattha’s research interests lie in the development of innovative drug delivery systems, particularly focusing on nanotechnology. His work explores nanoparticle-mediated therapies, including photothermal and photodynamic treatments, aiming to enhance the efficacy and safety of antifungal and anticancer drugs. He is also investigating the safety profiles of surfactants in nano-formulations, contributing to the advancement of safer pharmaceutical products.
Awards
Throughout his academic and professional journey, Chattha has been recognized for his contributions to pharmaceutical sciences. He has received accolades for his research presentations at international conferences, including the Third International Innovation in Pharmacy Conference in 2022. These awards underscore his commitment to advancing pharmaceutical knowledge and his active participation in the scientific community.
Top Noted Publications
Chattha has contributed to several peer-reviewed publications in reputable journals. His recent work includes:
1. Nanoparticle-Mediated Photothermal Therapy and Photodynamic Therapy: A Novel Strategy for Antifungal Drug Delivery and Treatment
Status: Accepted (2025)
Key Details:
-
Focus: Combines photothermal therapy (PTT) and photodynamic therapy (PDT) using nanoparticles (NPs) for the treatment of fungal infections.
-
Innovation: Dual-action therapy enhances antifungal efficacy while minimizing systemic toxicity.
-
Mechanism:
-
Nanoparticles used: Gold NPs, carbon-based NPs, and porphyrin-loaded nano-formulations.
-
Advantages: Targeted delivery, minimal resistance development, reduced dosage and side effects.
-
Applications: Treating resistant fungal infections in clinical settings, especially in immunocompromised patients.
2. Safety Concerns of Surfactants Used in Various Types of Nano-formulations: A Comprehensive Review
Status: Submitted (2025)
Key Details:
-
Focus: Reviews the toxicity and biocompatibility of surfactants used in nano-formulations across pharmaceutical, cosmetic, and food industries.
-
Surfactants covered: Tween, Span, SDS, Pluronic, and bile salts.
-
Concerns Addressed:
-
Cytotoxicity and immunogenicity.
-
Effects on biodistribution and clearance of nanoparticles.
-
Interaction with biological membranes and long-term exposure risks.
-
Recommendations: Emphasizes the need for safer, biodegradable surfactants and standardized toxicity assessments.
-
Outcome: Proposes guidelines for regulatory screening and clinical translation of nano-formulated products.
3. Nanorobots: An Innovative Approach for DNA-Based Cancer Treatment
Published: 2023
Key Details:
-
Focus: Discusses the design and functionality of DNA-based nanorobots for targeted cancer therapy.
-
Mechanism:
-
Uses DNA origami and molecular logic gates to recognize tumor-specific markers.
-
Nanorobots deliver therapeutic payloads (e.g., siRNA, chemotherapeutics) directly into cancer cells.
-
Key Features:
-
Preclinical Results: Demonstrated efficient tumor regression in murine models with minimal off-target effects.
-
Future Prospects: Customizable platforms for precision oncology and potential integration with CRISPR or immunotherapy strategies.
Conclusion
Ghulam Muhayyudin Chattha exhibits clear potential and emerging excellence as a pharmaceutical researcher. His active publication record, diverse research focus, and international exposure support his candidacy for the Best Researcher Award. While there is room for growth in terms of deeper research engagement and language fluency, his trajectory shows dedication, multidisciplinary skill development, and consistent academic and professional improvement.